/ obesity drugs

/ Market Analysis

Why Are Novo Nordisk Shares Rising in Premarket? GLP-1 Pill Launch Begins in U.S.

Novo Nordisk shares rose nearly 5% in premarket trading after the company launched its Wegovy weight-loss pill in the U.S.

January 06, 2026

The Weight Loss Market Can Surge to $400 B by 2032, and these Stocks Will Rule it

Despite Novo Nordisk's momentum, Eli Lilly seems a better long-term bet. Pfizer could surprise everyone from an undervalued position.

July 12, 2024

LLY vs NVO: Which One is Likely to Become a $1T Company First

Tackling growing waistlines is expected to yield much shareholder value.

February 08, 2024